Robert P. Ragusa, an insider at Grail Inc (GRAL), has sold 697,866 shares of the company at a price of $95.28 each, resulting in a total transaction value of $66.49 million. Following this sale, Ragusa retains an equal number of shares in Grail Inc.
Grail Inc operates as a commercial-stage healthcare company focused on developing technology for early cancer detection. Headquartered in Menlo Park, California, the firm employs approximately 1,000 full-time staff and went public on June 12, 2024. Its flagship product, the Galleri test, allows for early detection of multiple cancer types, potentially improving treatment outcomes.
As of December 4, 2025, Grail Inc has a market capitalization of $3.9 billion and a trailing twelve-month earnings per share (EPS) of -11.63. The company is set to report its upcoming earnings on May 11, 2026, with an EPS estimate of -3.08 and projected revenue of $38.3 million.
Insider transactions, such as this sale, are reported to the SEC and can provide insight into the actions of company executives. However, it is essential for investors to consider these transactions alongside other fundamental and technical indicators rather than in isolation.